Profile
Jörn Drappa is the founder of Viela Bio, Inc. (founded in 2018) where he held the title of Chief Medical Officer and Head of Research & Development from 2018 to 2021.
He also held former positions at Amgen, Inc. as Associate Director-Medical from 2003 to 2006, at Genentech, Inc. as Senior Director-Medical from 2008 to 2011, at Alpine Immune Sciences, Inc. as Director from 2022 to 2024, at Horizon Therapeutics Plc as Executive Vice President-Research & Development in 2021, at Medimmune, Inc. as Vice President-Clinical Development from 2011 to 2018, and at Ventyx Biosciences, Inc. as Chief Medical Officer from 2021 to 2022.
Dr. Drappa obtained a doctorate degree from Universität zu Köln in 1991 and another doctorate degree from Weill Cornell Medicine.
Former positions of Jörn Drappa
Companies | Position | End |
---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 2024-05-19 |
VENTYX BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2022-05-04 |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 2021-08-31 |
VIELA BIO, INC. | Founder | 2021-03-14 |
Medimmune, Inc. | Chief Tech/Sci/R&D Officer | 2018-01-31 |
Training of Jörn Drappa
Universität zu Köln | Doctorate Degree |
Weill Cornell Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
AMGEN INC. | Health Technology |
VENTYX BIOSCIENCES, INC. | Health Technology |
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
Private companies | 4 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Medimmune, Inc. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Jörn Drappa